New Agreement to advance inhibitor of novel target with global pharma company

New Agreement to advance inhibitor of novel target with global pharma company

Physiomics is pleased to announce that it has signed a substantial new contract with a major global pharmaceutical company. The programme of studies will begin immediately and take an estimated 9 months to reach a conclusion. Physiomics will determine the optimal dosing regimen of a new compound currently under development by this client.

Read more.